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Survival of mouse pancreatic islet allografts in recipients treated
with allogeneic small lymphocytes and antibody to CD40 ligand
(transplantation/tolerance/islets of Langerhans/diabetes mellitus)
DAVID C. PARKER*t, DALE L. GREINERt, NANCY E. PHILLIPS*, MICHAEL C. APPELt, ALAN W. STEELE*,
FIONA H. DURIE§, RANDOLPH J. NOELLE§, JOHN P. MORDESt, AND ALDO A. ROSSINIt¶
Departments of *Molecular Genetics and Microbiology and ::Medicine, University of Massachusetts Medical School, 55 Lake Avenue, Worcester, MA 01655; and
§Department of Microbiology, Dartmouth Medical School, Lebanon, NH 03756
Communicated by Roger H. Unger, The University of Texas Southwestern Medical Center, Dallas, TX, June 22, 1995
ABSTRACT Combined treatment with allogeneic small
lymphocytes or T-depleted small lymphocytes plus a blocking
antibody to CD40 ligand (CD40L) permitted indefinite pan-
creatic islet allograft survival in 37 of 40 recipients that
differed from islet donors at major and minor histocompat-
ibility loci. The effect of the allogeneic small lymphocytes was
donor antigen-specific. Neither treatment alone was as effec-
tive as combined treatment, although anti-CD40L by itself
allowed indefinite islet allograft survival in 40%o of recipients.
Our interpretation is that small lymphocytes expressing do-
nor antigens in the absence of appropriate costimulatory
signals are tolerogenic for alloreactive host cells. Anti-CD40L
antibody may prevent host T cells from inducing costimula-
tory signals in donor lymphocytes or islet grafts.
A long-term goal in allotransplantation is to develop methods
of inducing antigen-specific tolerance to replace generalized
immunosuppression. Recent advances in understanding how
antigen-presenting cells (APCs) regulate T-cell activation now
provide new strategies for inducing transplantation tolerance.
To proliferate and differentiate into destructive effector
cells, T cells depend on multiple signals from APCs. APCs use
nonclonal recognition systems to detect tissue damage or
infectious organisms (1). These signals are termed costimula-
tion (2). When an antigen receptor is ligated, responding T
cells continuously monitor for these signals in the environ-
ment. Costimulatory signals include the interaction between
CD28 on responding T cells and B7 family members on APCs.
This interaction enhances autocrine interleukin 2 synthesis and
secretion by the responding T cell (3). Costimulatory signals
can also regulate effector functions elicited by antigen (4).
Only dendritic cells constitutively express high levels of
costimulatory molecules (5, 6), and their expression can be
further up-regulated (6, 7). On macrophages, B lymphocytes,
endothelial cells, and keratinocytes, costimulatory molecules
can be induced by infection, adjuvant, inflammatory cytokines,
or activated T cells (3, 8-11).
T cells become anergic or die when they recognize antigen
in the absence of costimulation in vitro (2, 12). T cells escaping
clonal deletion in the thymus disappear or become anergic
when they recognize self-antigens on healthy APCs in vivo (13,
14). This is thought to be a major mechanism of self-tolerance.
These observations suggest that tissue allografts should be
tolerogenic if care is taken to avoid transplanting cells with
constitutive costimulatory activity. The concept of costimula-
tion was first proposed in the context of "passenger leuko-
cytes" and allograft rejection (15), and its importance has been
underscored by demonstrations that blockade of B7-CD28
interaction allows survival of cardiac allografts (16) and xe-
nogeneic human islets (17) in mice. Blockade was achieved
using CTLA4-Ig fusion protein, CTLA4 being a CD28-like
receptor found on activated T lymphocytes (18).
Activated CD4+ T cells express a membrane-bound protein,
CD40 ligand (CD40L, gp39), which engages CD40 on resting
B cells and accounts for most cell contact-dependent T-cell
help for small B cells (19-21). CD40L induces expression ofB7
and other costimulatory activities of B cells; it also enhances
expression of costimulatory molecules on other APCs (9, 22).
Here we report the survival of allogeneic islet grafts in
chemically diabetic mice pretreated with allogeneic small
lymphocytes, an antibody to the CD40L to prevent T-cell-B-
cell interactions, or both treatments in combination. When
anti-CD40L was combined with transfusion of small lympho-
cytes of donor type, long-term islet graft survival was obtained
in nearly all recipients.
MATERIALS AND METHODS
Mice. C57BL/6 (H-2b), BALB/c (H-2d), (BALB/c x
C57BL/6)F1, and (C57BL/6 x C3H)Fj mice were obtained
from the National Cancer Institute, Frederick, MD. C3H mice
are H-2k. Animals were housed in microisolators and provided
with autoclaved food and water ad libitum.
Preparation of Lymphocytes and Assays for APC Function.
Spleen cells from 8-wk-old female mice were depleted of
erythrocytes and fractionated by centrifugal elutriation (23,
24). A small cell fraction (fraction 19) was collected at 19
ml/min at 3200 rpm in a JE-6B rotor or at 77 ml/min at 3200
rpm with a JE-5.0 rotor (Beckman). A second fraction (frac-
tion 20) was collected at 20 ml/min. The fractions were
composed of small lymphocytes with a symmetric size distri-
bution (mean cell volume, 115-120 ,um3; Coulter Counter and
Multisizer; Coulter). In some experiments, small lymphocyte
fractions were depleted of T cells by treatment with anti-T-cell
monoclonal antibodies and complement (25). Before T-cell
depletion, fraction 19 was reduced in T cells (39% CD3+ in
unfractionated spleen; 14% CD3+ in fraction 19; mean of
three experiments). The T-depleted fraction 19 cells were 89%
B220+, 1.1% CD3+, and 10% null, presumably natural killer,
cells. To monitor radioresistant APC function, fractionated
cells were exposed to 3000 rads (1 rad = 0.01 Gy) from a 137CS
source and tested for ability to induce proliferation of the H-2b
alloreactive Th2 line, D10.G4 (American Type Culture Col-
lection). Various numbers of spleen cells were added to 1 x 105
D10.G4 cells in 200 ,ul of culture medium, and [3H]thymidine
incorporation was measured 72 hr later (25).
Abbreviations: APC, antigen-presenting cell; MHC, major histo-
compatibility complex.
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Islet Transplantation. Male C57BL/6 mice were rendered
diabetic (plasma glucose, >22.2 mM on three occasions within
1 wk) with intraperitoneal streptozotocin (140 mg/kg). Strep-
tozotocin diabetic mice were not ketotic and did not require
exogenous insulin for survival. They lost weight after onset of
hyperglycemia but uniformly gained weight after successful
islet transplantation. At the end of the protocol, pancreatic
morphology in all animals revealed shrunken islets that ap-
peared devoid of their normal core of 3 cells. BALB/c islets
were isolated by collagenase digestion (26) and implanted
immediately after isolation (30 per g of body weight) beneath
the renal capsule of C57BL/6 mice that had been diabetic for
14-25 days. Graft survival was defined as maintenance of
plasma glucose <13.9 mM. Mice that died for unknown
reasons but normoglycemic at the last measurement are shown
in the figures as falling to 0 mM but not included in survival
statistics.
Treatment Protocols. Five to 8 days before islet transplan-
tation, diabetic mice were injected once via the tail vein with
40-88 x 106 allogeneic, elutriated small lymphocytes or
erythrocyte-depleted unfractionated spleen cells. Beginning
on the day of lymphocyte injection, certain mice received 250
jig of the MR1 hamster anti-CD40L monoclonal antibody (19)
intraperitoneally twice weekly for 2-7 wk or until graft failure.
RESULTS
Effect of Pretreatment with Allogeneic Lymphocytes on
Islet Allograft Survival. We first measured survival of
BALB/c (H-2d) islet grafts in diabetic C57BL/6 (H-26) mice,
some of which were transfused with (BALB/c x C57BL/6)Fl
small splenic lymphocytes. F1 lymphocytes were used to avoid
graft vs. host reactions. Because the ability of donor lympho-
cytes to tolerize could depend on their APC activity, this
function was determined for each injected cell population.
Fraction 19 was devoid of radioresistant APC function as
documented by its inability to simulate proliferation of an
alloreactive Th2 cell line; fraction 20 was nearly indistinguish-
able in size but had low APC activity (data not shown).
Because the APC activity of activated B cells and other splenic
APC is relatively radioresistant, these data suggest that frac-
tion 19 was depleted of cells with constitutive APC activity (27,
28).
Diabetic mice given only islets rejected allografts within 13
days (9±2 days; range, 5-13 days; n = 23; Fig. 1). Mice
transfused with higher doses of fraction 19 lymphocytes (75-88
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x 106) showed longer graft survival (15±5 days; range, 7-21
days; n = 13), but the effect was temporary, and all islet grafts
were rejected by day 21. Animals treated with smaller numbers
of fraction 19 lymphocytes (40-44 x 106), with fraction 20
lymphocytes (75-88 x 106), or with unfractionated spleen cells
rejected grafts with the same kinetics as did untreated recip-
ients.
Pretreatment with Allogeneic Small Lymphocytes in Com-
bination with Anti-CD40L. We expected allogeneic small
lymphocytes to induce graft tolerance. We hypothesized that
their failure to do so resulted from host T cells inducing or
enhancing expression of costimulatory signals in the transfused
leukocytes. To test this, we prevented the interaction of
CD40L on host T cells with CD40 on donor leukocytes using
an antibody against CD40L (19). Antibody was used in com-
bination with allogeneic small lymphocytes to allow the pre-
sentation of alloantigen while preventing T cells from inducing
costimulatory activity.
Again, all untreated recipients rejected islet allografts (n =
22; Fig. 24). Treatment with anti-CD40L antibody by itself
produced indefinite graft survival in 40% of recipient animals
(n = 25; Fig. 2B) and delayed rejection in the remaining
recipients (mean failure at 24±30 days; range, 10-125 days).
This result suggests that anti-CD40L may modulate islet cell
graft rejection in the absence of transfused allogeneic lym-
phocytes.
When anti-CD40L was injected in combination with allo-
geneic lymphocytes, we observed 96% long-term survival of
islet grafts (n = 23), the one failure occurring on day 118 (Fig.
3A).
In additional experiments, 5 of 8 mice given one injection of
small lymphocytes plus four injections of anti-CD40L antibody
over 2 wk retained their grafts for the duration of the 6-wk
experiment. Mice receiving unfractionated spleen cells and
anti-CD40L antibody for 2 wk (n = 6) or 7 wk (n = 5) were
similar in outcome; 2 mice in each group rejected grafts within
40 days. These results suggest that shorter courses of anti-
CD40L antibody combined with small lymphocytes promote
islet graft survival and that fractionated small lymphocytes
may be more effective than unfractionated spleen cells.
Effect of Allogeneic Lymphocytes in Combination with
Anti-CD40L Is Donor Antigen-Specific. Transfusion of
(C57BL/6 x C3H)F1 lymphocytes in combination with anti-
CD40L was not more effective than anti-CD40L antibody
alone in prolonging BALB/c islet graft survival (5 of 9 mice
rejected grafts; time to-failure, 20±13 days; range, 10-40 days;
0 5 10 15 20 25 30
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FIG. 1. Islet allograft survival (defined as plasma glucose <13.9 mM). Streptozotocin diabetic recipients were transfused with Fl allogeneic
spleen cells or small lymphocyte fractions of F1 allogeneic spleen cells bearing islet donor alloantigens 5-8 days before transplantation.
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- FRACTION 19 CELLS, 75-88 X 106 (N=13)
FRACTION 20 CELLS, 75488 X 106 (N=7)
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FIG. 2. Anti-CD40L by itself enhances islet allograft survival.
Transplantation was done on day 0, and blood glucose of individual
mice is shown. (A) Rejection of islet allografts in untreated control
animals (n = 22, a separate control group from that shown in Fig. 1).
(B) Animals treated with 250 jig of anti-CD40L antibody twice weekly
for 1 wk before and 6 wk after transplantation (n = 25). 0, Mice from
which functioning islet allografts were removed by unilateral nephrec-
tomy to confirm allograft survival on the days indicated by arrows (n
= 4). Normoglycemic animals dead of unknown cause are shown as
dropping to 0 mM glucose.
Fig. 3B). Transfusion of (C57BL/6 x C3H)F1 lymphocytes
without coadministration of anti-CD40L resulted in rapid
rejection of BALB/c islets in all C57BL/6 recipients (Fig. 3C).
T Cells Are Not Required in the Spleen Cell Inoculum for
Graft Survival. The small lymphocyte fraction includes T cells
that might act as "veto" (29, 30) or suppressor cells. However,
T-cell-depleted F1 small lymphocytes were as effective as
complement-treated control F1 small lymphocytes for inducing
allograft survival in combination with anti-CD40L (Fig. 4).
Recipient Antigens on Transfused Lymphocytes Are Not
Required. Some models of tolerance induction by donor-
specific transfusion require donor and recipient antigens on
the same tolerizing cell (31, 32). To test this requirement, we
next studied fully allogeneic lymphocytes, avoiding graft vs.
host reactivity by T-depleting the donor inoculum. T-depleted,
allogeneic lymphocytes in combination with anti-CD40L re-
sulted in long-term graft survival (one failure at 128 days; Fig.
SA). These results were comparable to those obtained using F1
lymphocytes (Fig. 4). In contrast, T-depleted allogeneic lym-
phocytes without anti-CD40L resulted in rapid rejection of
islet allografts in all recipients (Fig. SB).
Survival of Islet Allografts after Discontinuation of Anti-
CD40L Injections. To determine if anti-CD40L acts as a
transiently immunosuppressive agent, mice were monitored
after antibody was discontinued (Figs. 2-5). In all groups, with
or without allogeneic lymphocyte injections, most animals
whose grafts were functional when antibody was stopped
remained normoglycemic thereafter.
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FIG. 3. Islet allograft survival. (A) Animals injected with 75-88 x
106 small lymphocytes (fraction 19) from (BALB/c x C57BL/6)F1
mice 5-8 days before transplantation in combination with anti-CD40L
antibody twice weekly for 7 wk beginning on the day of lymphocyte
injection (n = 17). 0, Mice from which functioning islet allografts were
removed by unilateral nephrectomy to confirm allograft survival on
the days indicated by arrows (n = 6). (B) Animals injected with
(C57BL/6 x C3H)F1 small lymphocytes (fraction 19) lacking BALB/c
islet donor antigens in combination with anti-CD40L (n = 9). (C)
Animals injected with (C57BL/6 x C3H)F1 small lymphocytes (frac-
tion 19) lacking BALB/c islet donor antigens without anti-CD40L (n
= 8).
Confirmation of Islet Allograft Function. Because all ani-
mals that became nondiabetic after transplantation gained
weight, decreased metabolic demands cannot explain the
observed normoglycemia. To confirm islet graft function and
the absence of insulin secretion by residual native islets, the
kidneys bearing islet implants were removed after 6-8 wk from
10 normoglycemic animals (Figs. 2B and 3A, 0). In every case,
removal of the grafted islets resulted in diabetes recurrence
(3.3 ± 1.9 days; range, 2-8 days).
Histology of Transplanted Islets. Islet allografts were stud-
ied histologically in these 10 animals and in 58 instances of
graft failure. BALB/c islet allografts from normoglycemic
mice given F1 small lymphocytes and anti-CD40L antibody
appeared intact, showed no mononuclear infiltration, and
contained well-granulated insulin- and glucagon-positive cells
(data not shown). Graft sites from all 58 hyperglycemic
animals evidenced either no residual islet tissue or only small
remnants of islet tissue heavily infiltrated by mononuclear
cells. In selected cases we performed immunohistochemical
analyses for insulin, and none was detected.
DISCUSSION
Combined treatment with allogeneic small lymphocytes and a
blocking antibody to CD40L allows permanent islet allograft
survival between mouse strains that differ in major histocom-
9562 Immunology: Parker et al.
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FIG. 4. T-cell-depleted F1 small lymphocytes are effective in
combination with anti-CD40L. (A) Animals injected with anti-CD40L
and (BALB/c x C57BL/6)F1 complement-treated small lymphocytes
(n = 8). (B) Animals treated with anti-CD40L and (BALB/c x
C57BL/6)Fl small lymphocytes treated with anti-T-cell antibodies and
complement (n = 10).
patibility complex (MHC)-encoded and minor transplantation
antigens. Of 40 treated mice, 37 had permanent islet allograft
survival, and 3 displayed delayed rejection (days 50, 127, and
130). In contrast, grafts were promptly rejected in all untreated
animals. There was no evidence of graft rejection in the groups
given anti-CD40L antibody and small lymphocytes after anti-
CD40L was discontinued.
The effect of allogeneic small lymphocytes was donor anti-
gen-specific. Small lymphocytes from F1 animals of the donor
and recipient strains and fully allogeneic, T-depleted small
lymphocytes of the donor strain were equally effective when
used in combination with anti-CD40L antibody. This suggests
that non-T cells (B cells) in the donor splenocytes permitted
permanent islet allograft survival when administered in com-
bination with anti-CD40L antibody. In support of this hypoth-
esis, we have recently shown that treatment with the anti-
CD40L antibody prevents development of alloreactive cyto-
lytic T lymphocytes after injection of allogeneic T-depleted
spleen cells and induces specific tolerance to those alloantigens
as measured by subsequent mixed lymphocyte responses in
vitro (33).
We did not test for the nonspecific effects of hamster
immunoglobulin on islet graft survival in these experiments,
but in other studies nonspecific immunoglobulin had no effect
on islet graft survival (unpublished data). Additionally, ham-
ster immunoglobulin has no immunosuppressive effects on
other T-dependent immune responses (34, 35), despite reports
that it accelerates collagen-induced arthritis (36).
How do small allogeneic lymphocytes plus anti-CD40L
enhance graft survival? Anti-CD40L may have a direct, inac-
tivating effect on T cells responding to injected lymphocytes
and allograft. CD40L is expressed on activated but not resting
20 -10
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FIG. 5. Fully allogeneic small lymphocytes permit islet allograft
survival in combination with anti-CD40L. (A) Animals treated with
anti-CD40L and T-depleted BALB/c small lymphocytes (n = 5). (B)
Animals treated with T-depleted BALB/c small lymphocytes without
anti-CD40L (n = 5).
T lymphocytes (19, 37, 38). Injected allogeneic cells would
induce CD40L expression on alloreactive T cells, rendering
them susceptible to anti-CD40L. We think this is unlikely. (i)
The antibody is not cytotoxic and does not clear CD40L+
cytokine-producing cells in vivo (39). (ii) Although it blocks
primary antibody responses, primed T cells can be recovered
from animals immunized in the presence of anti-CD40L (34).
(iii) As reported here, unfractionated spleen cells were nearly
as effective as small lymphocytes in blocking graft rejection
when combined with anti-CD40L. Unfractionated spleen cells
would be expected to be more effective at inducing CD40L on
alloreactive T cells, rendering them more susceptible to anti-
CD40L antibody elimination.
We hypothesize that anti-CD40L blocks interaction of
CD40L on alloreactive T cells with CD40 on donor leukocytes,
preventing the induction or enhanced expression of costimu-
latory signals on those cells. The host T cells require CD40-
dependent costimulatory signals to proliferate and differenti.
ate into effector cells capable of graft rejection or at least to
avoid inactivation as a result of antigen recognition on small B
lymphocytes that lack costimulatory activity. To test this
hypothesis, a disrupted CD40 gene (40) must be bred onto
BALB/c mice to study CD40/CD40L interactions in our
transplantation model.
The partial but substantial effect oanti-CD4L by itself on
islet graft survival suggests that CD4OL/CD40 interactions
between donor islets and the host immune system may be
important. Recent data show that dendritic cells (a passenger
leukocyte in islet grafts) can be activated through CD40 (7).
Alternatively, because CD40 is also on T cells (41) and
macrophages (42), and induces secretion of chemotactic cy-
tokines from monocytes and dendritic cells (7), CD40L/CD40
I
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interactions could be important in inflammation and graft
destruction by alloreactive effector T cells.
Our limited success in prolonging graft survival across a
complete MHC mismatch with small lymphocytes alone con-
trasts with earlier reports. Skin graft survival has been ob-
served across an isolated class II difference (43) and the male
minor transplantation antigen (44) by pretreatment with APC-
depleted spleen cells or purified B cells, respectively. We have
also been able to induce tolerance to a transgene-encoded
antigen expressed in B cells by transferring transgenic B cells
into nontransgenic littermates without anti-CD40L (V. Yus-
chenk-off fd D.C.P., unpublished). The difference between
those results and our observations here may be due to the high
frequency of alloreactive T cells in complete MHC mis-
matches. Some of these alloreactive T cells may be primed or
recently activated by crossreacting environmental antigens
(45) and therefore difficult to tolerize (44). They may also be
more effective than naive T cells in inducing costimulatory
activity and converting transfused lymphocytes into immuno-
genic APCs. Others have reported tolerance induction across
MHC barriers by injecting spleen cells without removing
nonlymphoid APCs (32, 46), but we find this possible only if
CD40L/CD40 interaction is blocked.
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